{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:47:16Z","timestamp":1794642436457,"version":"4.9.1"},"reference-count":12,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,8,23]],"date-time":"2009-08-23T00:00:00Z","timestamp":1250985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cutan Pathol"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:p> <jats:bold>Background:<\/jats:bold> Imatinib mesylate (Gleevec<jats:sup>\u00ae<\/jats:sup>) is a selective Bcr\u2010Abl protein tyrosine\u2010kinase inhibitor, and it also inhibits the receptor tyrosine kinases for stem cell factor (c\u2010kit) and platelet\u2010derived growth factor (PDGFR). It is being investigated for use in the treatment of sclerosing dermatoses.<\/jats:p><jats:p> <jats:bold>Observation:<\/jats:bold> A 44\u2010year\u2010old woman with a history of chronic myelogenous leukemia (CML) was referred for the evaluation of a pruritic eruption that developed over 6 months. Examination revealed atrophic plaques confined to the groin, vulva, axillae, inframammary region, trunk, antecubital and popliteal fossae, and posterior thighs bilaterally. A biopsy showed lichen sclerosus et atrophicus (LSetA). At the time of presentation, the patient was receiving imatinib mesylate 400 mg daily for CML.<\/jats:p><jats:p> <jats:bold>Conclusion:<\/jats:bold> This is the first report of development of LSetA, a sclerosing dermatosis, while receiving a therapeutic dose of imatinib mesylate, a drug thought to have anti\u2010sclerotic properties.<\/jats:p><jats:p>Skupsky H, Abuav R, High W, Pass C, Goldenberg G. Development of lichen sclerosus et atrophicus while receiving a therapeutic dose of imatinib mesylate for chronic myelogenous leukemia.<\/jats:p>","DOI":"10.1111\/j.1600-0560.2009.01398.x","type":"journal-article","created":{"date-parts":[[2009,8,24]],"date-time":"2009-08-24T04:00:43Z","timestamp":1251086443000},"page":"877-880","source":"Crossref","is-referenced-by-count":15,"title":["Development of lichen sclerosus et atrophicus while receiving a therapeutic dose of imatinib mesylate for chronic myelogenous leukemia"],"prefix":"10.1111","volume":"37","author":[{"given":"Hadas","family":"Skupsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Abuav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"High","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Pass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,9]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01469.x"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2003.01211.x"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2003.01211.x"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2004.03.006"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22314"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23696"},{"key":"e_1_2_4_8_2","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/archderm.144.9.1106","article-title":"Imatinib as a potential treatment for sclerodermatous chronic graft\u2010vs\u2010host disease","volume":"144","author":"Moreno\u2010Romero JA","year":"2008","journal-title":"Arch Dermatol"},{"key":"e_1_2_4_9_2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/rheumatology\/ken104","article-title":"Imatinib for the treatment of refractory, diffuse systemic sclerosis","volume":"47","author":"Sfikakis PP","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000111507"},{"issue":"11","key":"e_1_2_4_11_2","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0560.2007.00948.x","article-title":"Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.","volume":"35","author":"Thomison J","year":"2008","journal-title":"J Cutan Pathol."},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2007.00948.x"},{"key":"e_1_2_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.02.020"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0560.2009.01398.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0560.2009.01398.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T23:47:35Z","timestamp":1698709655000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0560.2009.01398.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,9]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1600-0560.2009.01398.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0560.2009.01398.x","archive":["Portico"],"relation":{},"ISSN":["0303-6987","1600-0560"],"issn-type":[{"value":"0303-6987","type":"print"},{"value":"1600-0560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,9]]}}}